An experimental six-strain Lyme disease vaccine developed by Pfizer has shown over 70% efficacy in individuals aged 5 years ...
A Lyme disease vaccine from Pfizer and French biotech company Valneva showed promising phase three results in international trials that included New York residents in Halfmoon and Cooperstown. The ...
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, ...
An experimental six-strain Lyme vaccine has demonstrated more than 70% efficacy in preventing Lyme disease in people aged ...
Lyme disease infects hundreds of thousands of people each year and now scientists may be on the verge of a breakthrough with ...
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated ...
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...
An experimental vaccine for Lyme disease is broadly effective, pharmaceutical companies Pfizer and Valneva announced Monday; ...
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose ...
Valneva and Pfizer's three-dose shot targets the outer surface protein A (OspA) of the Borrelia burgdorfii bacteria that ...
A novel oral vaccine, ETVAX, has demonstrated its potential to reduce paediatric cases of moderate-to-severe enterotoxigenic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results